the aid library

LIST OPTIONS

Filter

3975

External Link

Hospital safety Index Guide for Evaluators. Forms

World Health Organization WHO World Health Organization and Pan American Health Organization (2015) C_WHO

checklist

Download (379)

View PDF (363)

The Georgian national HIV/AIDS strategic plan for 2016–2018

CCM Georgia (2019) C2

Endorsed by the CCM Georgia on April 15th 2015 Accessed: 26.09.2019

Download (445)

View PDF (395)

Principles in using psychotropic medication in children and adolescents

B. Vitiello IACAPAP (2012) C2

Introduction Chapter A.7

Download (532)

View PDF (400)

Inter-Agency Reproductive Health Kits 6th Edition - Manual

Inter-Agency Working Group on Reproductive Health in Crisis IAWG and UNFPA (2021) C1

Download (348)

View PDF (469)

Universal Periodic Review of Albania - 33rd Session

Albania Center for Population and Development (ACPD); Albanian Association of People Living with HIVAIS; Roma Active Albania; STOP AIDS; Aksion Plus; et al. (2019) C2

Joint Stakeholder Submission Accessed: 29.09.2019

Download (495)

View PDF (538)

Recommandations et orientations concernant l’autodépistage du virus de l’hépatite C

World Health Organisation (WHO) (2021) C_WHO

Malgré les progrès récents vers la mise au point d’un traitement hautement efficace et abordable contre le virus de l’hépatite C, beaucoup de personnes infectées par ce virus ne connaissent pas leur statut. L’Organisation mondiale de la Santé (OMS) estime qu’en 2019, 58 millions ... more

Download (365)

View PDF (364)

Guidelines for COVID-19 testing and quarantine of air travellers - Addendum to the Aviation Health Safety Protocol

European Centre for Disease Prevention and Control ECDC (2020) CC

This joint ECDC-European Union Aviation Safety Agency (EASA) document aims to support Member States in determining a coordinated approach to reduce the risks related to the movement of people by air within and between the EU/EEA countries and the UK in the context of the COVID-19 pandemic, noting th... more

Download (630)

View PDF (1020)

Malawi Demographic and Health Survey 2010

National Statistical Office (NSO) and ICF Macro (2011) C1

Download (605)

View PDF (1583)

Spousal Violence and HIV: Exploring the Linkages in Five Sub-Saharan African Countries

MacQuarrie, Kerry L.D., Rebecca Winter, and Sunita Kishor ICF International (2013) C2

DHS Analytical Studies No. 36

Download (483)

View PDF (530)

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

Download (668)

View PDF (638)

Introducing and scaling up testing for human papillomavirus as part of a comprehensive programme for prevention and control of cervical cancer

World Health Organization WHO (2020) C_WHO

This guidance is intended to be used by programme managers following the decision to introduce human papillomavirus (HPV) virological testing as a screening assay in their national cervical cancer prevention and control programme. The guidance includes a step-by-step process to be followed after the... more

Download (760)

View PDF (1788)

Framework for a national plan for monitoring and management of insecticide resistance in malaria vectors

World Health Organization (WHO) (2017) C_WHO

Effective malaria prevention is threatened by widespread and increasing vector insecticide resistance. Failure to mitigate this threat will likely result in an increased burden of disease, with significant cost implications. This new framework provides support for the development of a national insec... more

Download (595)

View PDF (788)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more